TB-500 and Apixaban Interaction: Risks, Mechanisms, and Clinical Guidance
Medical review of the TB-500 (thymosin beta-4 active fragment) and apixaban interaction covering CYP3A4/P-gp metabolism, pharmacodynamic bleeding risk, monitoring protocols, and dose-adjustment considerations.